Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of Alabama at Birmingham CALR compound d4
- Development stage
- Unknown
- Lead developer
- University of Alabama at Birmingham
01
Overview
Univ. of Alabama at Birmingham CALR compound d4: sourced facts only. name: "BLI against CALR identified two high affinity binders, d4 and d6, with calculated dissociation constants of 83.2 nM (kon = 512790 M-1s-1, koff = 0.04265 s-1) and 31.2 nM (kon = 551797 M-1s-1, koff = 0.01723 s-1), respectively." [DOI:10.1158/1538-7445.am2026-5818]; target: "BLI against CALR identified two high affinity binders, d4 and d6, with calculated dissociation constants of 83.2 nM (kon = 512790 M-1s-1, koff = 0.04265 s-1) and 31.2 nM (kon = 551797 M-1s-1, koff = 0.01723 s-1), respectively." [DOI:10.1158/1538-7445.am2026-5818]; developer: "University of Alabama at Birmingham, Birmingham, AL." [DOI:10.1158/1538-7445.am2026-5818]
02
Targets
CALR (Calreticulin)
Beyond the preview
Go deeper on Univ. of Alabama at Birmingham CALR compound d4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of Alabama at Birmingham CALR compound d4.